Skip to main content
NCBI home page
Proceedings of the Royal Society of Medicine logoLink to Proceedings of the Royal Society of Medicine
. 1977;70(Suppl 5):40–44. doi: 10.1177/00359157770700S518

Problems with Beta Adrenergic Blocking Drugs and other Antihypertensive Drugs

B N C Prichard
PMCID: PMC1542839  PMID: 20919347

Full text

PDF
40

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. APTHORP G. H., CHAMBERLAIN D. A., HAYWARD G. W. THE EFFECTS OF SYMPATHECTOMY ON THE ELECTROCARDIOGRAM AND EFFORT TOLERANCE IN ANGINA PECTORIS. Br Heart J. 1964 Mar;26:218–226. doi: 10.1136/hrt.26.2.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ahlmark G., Saetre H., Korsgren M. Letter: Reduction of sudden Deaths after myocardial infarction. Lancet. 1974 Dec 28;2(7896):1563–1563. doi: 10.1016/s0140-6736(74)90299-2. [DOI] [PubMed] [Google Scholar]
  3. Amsterdam E. A., Gorlin R., Wolfson S. Evaluation of long-term use of propranolol in angina pectoris. JAMA. 1969 Oct 6;210(1):103–106. [PubMed] [Google Scholar]
  4. Beumer H. M. Adverse effects of beta-adrenergic receptor blocking drugs on respiratory function. Drugs. 1974;7(1):130–138. doi: 10.2165/00003495-197407010-00009. [DOI] [PubMed] [Google Scholar]
  5. Coltart D. J., Gibson D. G., Shand D. G. Plasma propranolol levels associated with suppression of ventricular ectopic beats. Br Med J. 1971 Feb 27;1(5747):490–491. doi: 10.1136/bmj.1.5747.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davidov M., Kakaviatos N., Finnerty F. A., Jr The antihypertensive effects of an imidazoline compound. Clin Pharmacol Ther. 1967 Nov-Dec;8(6):810–816. doi: 10.1002/cpt196786810. [DOI] [PubMed] [Google Scholar]
  7. Dintenfass L., Lake R. Letter: Beta blocker and blood viscosity. Lancet. 1976 May 8;1(7967):1026–1026. doi: 10.1016/s0140-6736(76)91906-1. [DOI] [PubMed] [Google Scholar]
  8. Eliasch H., Rosén A., Scott H. M. Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade. Br Heart J. 1967 Sep;29(5):671–683. doi: 10.1136/hrt.29.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Finch L., Haeusler G. Further evidence for a central hypotensive action of alpha-methyldopa in both the rat and cat. Br J Pharmacol. 1973 Feb;47(2):217–228. doi: 10.1111/j.1476-5381.1973.tb08319.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Forrest W. A. A total of 254 cases of angina pectoris treated with oxprenolol in hospital practice--a monitored release study. Br J Clin Pract. 1972 May;26(5):217–222. [PubMed] [Google Scholar]
  11. Fox K. M., Chopra M. P., Portal R. W., Aber C. P. Long-term beta blockade: possible protection from myocardial infarction. Br Med J. 1975 Jan 18;1(5950):117–119. doi: 10.1136/bmj.1.5950.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Frishman W. H., Weksler B., Christodoulou J. P., Smithen C., Killip T. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation. 1974 Nov;50(5):887–896. doi: 10.1161/01.cir.50.5.887. [DOI] [PubMed] [Google Scholar]
  13. Greenblatt D. J., Koch-Weser J. Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs. 1974;7(1):118–129. doi: 10.2165/00003495-197407010-00008. [DOI] [PubMed] [Google Scholar]
  14. Grüneberg R. N., Leigh D. A., Brumfitt W. Relationship of bacteriuria in pregnancy to acute pyelonephritis, prematurity, and fetal mortality. Lancet. 1969 Jul 5;2(7610):1–3. doi: 10.1016/s0140-6736(69)92592-6. [DOI] [PubMed] [Google Scholar]
  15. Heffernan A., Carty A., O'Malley K., Bugler J. A within-patient comparison of debrisoquine and methyldopa in hypertension. Br Med J. 1971 Jan 9;1(5740):75–78. doi: 10.1136/bmj.1.5740.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Henning M., Rubenson A. Evidence that the hypotensive action of methyldopa is mediated by central actions of methylnoradrenaline. J Pharm Pharmacol. 1971 Jun;23(6):407–411. doi: 10.1111/j.2042-7158.1971.tb08671.x. [DOI] [PubMed] [Google Scholar]
  17. Hjalmarson A., Waagstein F., Waldenström A. Proceedings: Effects of cardioselective beta-blockers on chest pain, ECG, and heart function in acute myocardial infarction. Br Heart J. 1976 May;38(5):530–531. [PubMed] [Google Scholar]
  18. Hunyor S. N., Hansson L., Harrison T. S., Hoobler S. W. Effects of clonidine withdrawal: possible mechanisms and suggestions for management. Br Med J. 1973 Apr 28;2(5860):209–211. doi: 10.1136/bmj.2.5860.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ingram G. I., Jones R. V. The rise in clotting factor 8 induced in man by adrenaline: effect of alpha- and beta-blockers. J Physiol. 1966 Nov;187(2):447–454. doi: 10.1113/jphysiol.1966.sp008102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Johnson P., Kitchin A. H., Lowther C. P., Turner R. W. Treatment of hypertension with methyldopa. Br Med J. 1966 Jan 15;1(5480):133–137. doi: 10.1136/bmj.1.5480.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lund-Larsen G., Sivertssen E. Hemodynamic effects of propranolol (Inderal) and H 56-28 (Aptin) in patients with acute myocardial infarction. A comparative study. Acta Med Scand. 1969 Sep;186(3):187–191. [PubMed] [Google Scholar]
  22. Lyon L. J., Nevins M. A. Alprenolol treatment of angina pectoris. JAMA. 1971 Mar 8;215(10):1669–1669. [PubMed] [Google Scholar]
  23. Maroko P. R., Kjekshus J. K., Sobel B. E., Watanabe T., Covell J. W., Ross J., Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971 Jan;43(1):67–82. doi: 10.1161/01.cir.43.1.67. [DOI] [PubMed] [Google Scholar]
  24. Oates J. A., Seligmann A. W., Clark M. A., Rousseau P., Lee R. E. The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. N Engl J Med. 1965 Sep 30;273(14):729–734. doi: 10.1056/NEJM196509302731402. [DOI] [PubMed] [Google Scholar]
  25. Onesti G., Schwartz A. B., Kim K. E., Paz-Martinez V., Swartz C. Antihypertensive effect of clonidine. Circ Res. 1971 May;28(5 Suppl):53–69. doi: 10.1161/01.res.28.5.ii-53. [DOI] [PubMed] [Google Scholar]
  26. PRICHARD B. N., GILLAM P. M. USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION. Br Med J. 1964 Sep 19;2(5411):725–727. doi: 10.1136/bmj.2.5411.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pelides L. J., Reid D. S., Thomas M., Shillingford J. P. Inhibition by -blockade of the ST segment elevation after acute myocardial infarction in man. Cardiovasc Res. 1972 May;6(3):295–301. doi: 10.1093/cvr/6.3.295. [DOI] [PubMed] [Google Scholar]
  28. Prichard B. N. Beta-adrenergic receptor blocking drugs in angina pectoris. Drugs. 1974;7(1):55–84. doi: 10.2165/00003495-197407010-00005. [DOI] [PubMed] [Google Scholar]
  29. Prichard B. N., Gillam P. M., Graham B. R. Beta receptor antagonism in hypertension; comparison with the effect of adrenergic neurone inhibition on cardiovascular responses. Int Z Klin Pharmakol Ther Toxikol. 1970 Dec;4(1):131–140. [PubMed] [Google Scholar]
  30. Prichard B. N., Johnston A. W., Hill I. D., Rosenheim M. L. Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison. Br Med J. 1968 Jan 20;1(5585):135–144. doi: 10.1136/bmj.1.5585.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Raftos J., Bauer G. E., Lewis R. G., Stokes G. S., Mitchell A. S., Young A. A., Maclachlan I. Clonidine in the treatment of severe hypertension. Med J Aust. 1973 Apr 21;1(16):786–793. doi: 10.5694/j.1326-5377.1973.tb110692.x. [DOI] [PubMed] [Google Scholar]
  32. Shinebourne E., Fleming J., Hamer J. Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart-disease. Lancet. 1967 Dec 9;2(7528):1217–1220. doi: 10.1016/s0140-6736(67)90561-2. [DOI] [PubMed] [Google Scholar]
  33. Simpson F. O. Beta-adrenergic receptor blocking drugs in hypertension. Drugs. 1974;7(1):85–105. doi: 10.2165/00003495-197407010-00006. [DOI] [PubMed] [Google Scholar]
  34. Taggart P., Carruthers M., Somerville W. Electrocardiogram, plasma catecholamines and lipids, and their modification by oxyprenolol when speaking before an audience. Lancet. 1973 Aug 18;2(7825):341–346. doi: 10.1016/s0140-6736(73)93190-5. [DOI] [PubMed] [Google Scholar]
  35. Taggart P., Carruthers M. Suppression by oxprenolol of adrenergic response to stress. Lancet. 1972 Aug 5;2(7771):256–258. doi: 10.1016/s0140-6736(72)91689-3. [DOI] [PubMed] [Google Scholar]
  36. Waal-Manning H. J., Simpson F. O. Practolol treatment in asthmatics. Lancet. 1971 Dec 4;2(7736):1264–1265. doi: 10.1016/s0140-6736(71)90585-x. [DOI] [PubMed] [Google Scholar]
  37. Whittington-Coleman P. J., Carrier O., Jr, Douglas B. H. The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis. 1973 Sep-Oct;18(2):337–345. doi: 10.1016/0021-9150(73)90109-3. [DOI] [PubMed] [Google Scholar]
  38. Wilhelmsson C., Vedin J. A., Wilhelmsen L., Tibblin G., Werkö L. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet. 1974 Nov 16;2(7890):1157–1160. doi: 10.1016/s0140-6736(74)90807-1. [DOI] [PubMed] [Google Scholar]
  39. de Grouchy J. Human chromosomes and their anomalies. Postgrad Med J. 1976;52 (Suppl 2):5–16. [PubMed] [Google Scholar]

Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES